Source: Patented Medicine Prices Review Board

Media Advisory: Technical Briefing for Media on Key Findings Observed in the Patented Medicine Prices Review Board's New Flagship Annual Report on Public Drug Plan Expenditures

OTTAWA, ONTARIO--(Marketwired - March 30, 2015) - Media are invited to attend a technical briefing on the key findings observed in CompassRx, the Patented Medicine Prices Review Board's (PMPRB's) new flagship annual National Prescription Drug Utilization Information System (NPDUIS) initiative report. CompassRx is the first report of its kind to identify the major drivers behind changes in prescription drug expenditures in public drug plans in Canada - an important element in allowing policy-makers and researchers to understand current trends and anticipate future cost pressures and expenditure levels.

Media representatives may participate in this technical briefing in person or by teleconference.

When: Tuesday, March 31, 2015, from 1:30 - 2:30 p.m. (EST)
Location: Eastman Boardroom
333 Laurier Avenue West, Suite 1400
Ottawa, Ontario

Notes to editor / news director

Media representatives are asked to register in advance with the PMPRB's Manager, Communications at 613-960-9728 or by e-mail at Supporting documents and details for joining the technical briefing by teleconference will be provided upon registration.

About the Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board protects and informs Canadians by ensuring the prices of patented medicines sold in Canada are not excessive and by reporting on pharmaceutical trends.

About the NPDUIS initiative

The National Prescription Drug Utilization System is a research initiative jointly conducted by the PMPRB and the Canadian Institute for Health Information. NPDUIS seeks to provide policy-makers and drug plan managers with information and insights on trends in prices, utilization, and costs.

Follow us on Twitter: @PMPRB_CEPMB

Contact Information:

Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board